2004 Competition Pharma 
European Pharmaceutical Review
APRIL 28, 2023
Pinsent Masons Charlotte Weekes, Senior Associate at Pinsent Masons shared with EPR : “The Commission’s ambitious pharma legislation review is the first significant review of the European system since 2004.” “It "Our concern is that the pharma legislation is not there yet."
pharmaphorum
DECEMBER 28, 2022
M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. Since the first wave of consolidation started in 1988, there has been a significant concentration of the pharma industry.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 24, 2023
The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation.
pharmaphorum
JANUARY 19, 2023
Run by Life Science Integrates, Pharma Integrates was in its 11th year in 2022. GIRFT and competition He went on: “Improvement needs competition – everything else is a proxy; it doesn’t work well. When Milburn and Blair introduced competition in 2004-2008 it did start to make a difference.” Highly unlikely.”
PM360
JUNE 29, 2022
However, patient uptake hasn’t matched rising market competition. These low adoption rates highlight the need for more migraine-drug awareness and suggest that pharma marketers should explore new strategies to boost patient uptake. And among patients who have tried preventive medications for migraine, 39% said they no longer took them.
PM360
SEPTEMBER 28, 2022
PM360 spoke to Kokino about the evolution of the biosimilars market from its nascent days, why the now increased competition within the market is causing some companies to reconsider developing biosimilars, what to look for over the next few years, and how Accord’s approach is a bit different from what other companies are doing.
European Pharmaceutical Review
DECEMBER 19, 2022
She has experience on issues arising during the lifecycle of medicinal products, including optimisation of IP regulatory rights, advertising, product liability, competition and market access issues. The Impact of Biosimilar Competition in Europe, IQVIA, December 2021. Directive 2001/83 (as amended). EMA Biosimilars Q&A.
Expert insights. Personalized for you.
98 
Let's personalize your content